skip to main content
Idioma:

American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3

Curtis, Jeffrey R. ; Johnson, Sindhu R. ; Anthony, Donald D. ; Arasaratnam, Reuben J. ; Baden, Lindsey R. ; Bass, Anne R. ; Calabrese, Cassandra ; Gravallese, Ellen M. ; Harpaz, Rafael ; Kroger, Andrew ; Sadun, Rebecca E. ; Turner, Amy S. ; Williams, Eleanor Anderson ; Mikuls, Ted R.

Arthritis & rheumatology (Hoboken, N.J.), 2021-10, Vol.73 (10), p.e60-e75 [Periódico revisado por pares]

United States: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
  • Título:
    American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3
  • Autor: Curtis, Jeffrey R. ; Johnson, Sindhu R. ; Anthony, Donald D. ; Arasaratnam, Reuben J. ; Baden, Lindsey R. ; Bass, Anne R. ; Calabrese, Cassandra ; Gravallese, Ellen M. ; Harpaz, Rafael ; Kroger, Andrew ; Sadun, Rebecca E. ; Turner, Amy S. ; Williams, Eleanor Anderson ; Mikuls, Ted R.
  • Assuntos: Coronaviruses ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - therapeutic use ; Full Length ; Health care ; Humans ; Immunization ; Immunomodulation ; Infectious diseases ; Iterative methods ; Musculoskeletal Diseases ; Online‐Only Special ; Patients ; Physicians ; Public health ; Rheumatic Diseases ; Rheumatology ; Task forces ; United States ; Vaccination ; Vaccine efficacy ; Vaccines ; Viral diseases
  • É parte de: Arthritis & rheumatology (Hoboken, N.J.), 2021-10, Vol.73 (10), p.e60-e75
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    ObjectType-Instructional Material/Guideline-3
    Supported by the American College of Rheumatology. The effort of some individual authors was supported in part by the NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases grant P30‐AR072583).
    The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry.
    Dr. Curtis has received consulting fees, speaking fees, and/or honoraria from AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Eli Lilly, and Novartis (less than $10,000 each) and from Amgen, Janssen, Pfizer, Myriad, and Sanofi (more than $10,000 each) and research grants from Genentech, Gilead, AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Eli Lilly, Amgen, Janssen, Pfizer, Myriad, and Sanofi. Dr. Johnson has received consulting fees, speaking fees, and/or honoraria from Ikarai and Boehringer Ingelheim (less than $10,000 each) and research grants from Bayer, Boehringer Ingelheim, Corbus, and GlaxoSmithKline. Dr. Baden has received salary support form the New England Journal of Medicine (less than $10,000). Dr. Calabrese has received consulting fees, speaking fees, and/or honoriaria from AbbVie and Sanofi Genzyme (less than $10,000 each). Dr. Gravallese has received salary support from the New England Journal of Medicine (more than $10,000). Dr. Mikuls has received consulting fees, speaking fees, and/or honoraria from Sanofi, Horizon, Pfizer, and Gilead (less than $10,000 each) and research support from Bristol Myers Squibb and Horizon. No other disclosures relevant to this article were reported.
  • Descrição: Objective To provide guidance to rheumatology providers on the use of coronavirus disease 2019 (COVID‐19) vaccines for patients with rheumatic and musculoskeletal diseases (RMDs). Methods A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious disease specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID‐19 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9‐point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings. Results Despite a paucity of direct evidence, 74 draft guidance statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID‐19 vaccines in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination. Conclusion These guidance statements, made in the context of limited clinical data, are intended to provide direction to rheumatology health care providers on how to best use COVID‐19 vaccines and to facilitate implementation of vaccination strategies for RMD patients.
  • Editor: United States: Wiley Subscription Services, Inc
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.